Logo: to the web site of Uppsala University

uu.sePublications from Uppsala University
Change search
Link to record
Permanent link

Direct link
Alternative names
Publications (10 of 13) Show all publications
Stenlid, R., El Amrani, S., Cerenius, S. Y., Aydin, B. K., Manell, H., Mörwald, K., . . . Bergsten, P. (2025). Cardiometabolic risk stratification in pediatric obesity: evaluating the clinical utility of fasting insulin and BMI-SDS. Cardiovascular Diabetology, 24(1), Article ID 324.
Open this publication in new window or tab >>Cardiometabolic risk stratification in pediatric obesity: evaluating the clinical utility of fasting insulin and BMI-SDS
Show others...
2025 (English)In: Cardiovascular Diabetology, E-ISSN 1475-2840, Vol. 24, no 1, article id 324Article in journal (Refereed) Published
Abstract [en]

Background

Patients with obesity during childhood have an increased risk of fatal and non-fatal cardiovascular events during adulthood. The severity of obesity is commonly determined by BMI. However, children with relatively low BMI may have high cardiometabolic risk. Indeed, BMI-based obesity classifications might miss children at high cardiometabolic risk. Insulin has been suggested as a marker of cardiometabolic risk. In this study, we therefore estimated and compared cardiometabolic risk using either the BMI standard deviation score (BMI-SDS) or fasting insulin in an international cohort of children and adolescents with obesity and lean controls.

Methods

Study participants (712 with obesity and 99 lean controls), aged 3 to 18 years, were categorized according to their BMI-SDS as lean or obesity class I, II, or III, or by their fasting insulin quartiles as quartile 1, 2, 3, or 4 with the lean subjects in a separate control group. Prevalence of cardiometabolic risk factors was assessed in each group. Sensitivity and specificity analyses for cardiometabolic risk were conducted for both BMI-SDS and fasting insulin. Multiple regression, logistic regression, and receiver operating characteristic (ROC) analyses were performed between fasting insulin, BMI-SDS and cardiometabolic risk factors.

Results

An elevated prevalence of the cardiometabolic risk factors dyslipidemia, dysglycemia and hypertension was observed in both increasing BMI-SDS classes and increasing fasting insulin quartiles. Fasting insulin demonstrated higher areas under the curve (AUC) for detecting dyslipidemia, dysglycemia, and the combination of dyslipidemia, dysglycemia, and hypertension, compared to BMI-SDS. BMI-SDS demonstrated a higher AUC for detecting hypertension compared to fasting insulin. The same patterns were seen for the logistic regression. However, fasting insulin had an overall stronger association with the cardiometabolic risk factors studied compared to BMI-SDS.

Conclusions

In children and adolescents with obesity, fasting insulin provides complementary information to BMI-SDS in identifying those with elevated cardiometabolic risk factors. While neither marker alone offers strong predictive accuracy, incorporating fasting insulin into clinical assessment may help prioritize individuals who require more detailed evaluation. An elevated fasting insulin value may warrant further investigation among children and adolescents with obesity, independent of obesity class based on BMI-SDS.

Place, publisher, year, edition, pages
BioMed Central (BMC), 2025
Keywords
Obesity, Pediatric obesity, Hypertension, Cardiometabolic risk, Cardiovascular disease, Dysglycemia, Dyslipidemia, Insulin, Cardiovascular risk factors, BMI-SDS
National Category
Endocrinology and Diabetes Cardiology and Cardiovascular Disease Pediatrics
Identifiers
urn:nbn:se:uu:diva-566343 (URN)10.1186/s12933-025-02882-7 (DOI)001547708400001 ()40781672 (PubMedID)2-s2.0-105012765077 (Scopus ID)
Funder
EU, FP7, Seventh Framework Programme, 279153Swedish Foundation for Strategic Research, CMP22-0014Swedish Research Council, 2016-01040
Note

Correction in: Cardiovascular Diabetology, vol. 24, article id 417, DOI: 10.1186/s12933-025-02975-3

Title in the list of papers of Rasmus Stenlid's thesis: Fasting insulin better predicts cardiometabolic risk factors in children and adolescents with obesity than BMI

Available from: 2025-09-08 Created: 2025-09-08 Last updated: 2026-04-22Bibliographically approved
Engsner, M., Ciba, I., Aydin, B. K., Stenlid, R., Soderhall, J., Bergsten, P. & Forslund, A. (2025). Evaluation of BMI Growth Charts for Children Living with Severe Obesity. CHILDHOOD OBESITY, 21(7), 629-639
Open this publication in new window or tab >>Evaluation of BMI Growth Charts for Children Living with Severe Obesity
Show others...
2025 (English)In: CHILDHOOD OBESITY, ISSN 2153-2176, Vol. 21, no 7, p. 629-639Article in journal (Refereed) Published
Abstract [en]

Introduction: Growth charts were not designed to monitor children and adolescents with severe obesity. We evaluate three commonly used international references and their implications for children with severe obesity and develop a BMI growth chart for children with severe obesity, which we call "Reference-point BMI from adjusted World Health Organization (WHO) population" (R-BMI).

Method: Growth charts from the WHO, International Obesity Task Force, and CDC were reviewed regarding population, statistical method, and cut-offs. We created the R-BMI chart from the WHO population, with adapted adjustment and reference-point cut-offs, and the layout was updated for better readability. Moreover, an interactive web app was developed for this project at the following link https://child-bmi.serve.scilifelab.se/ with the purpose of visually comparing different BMI references for children with obesity.

Results: Three different references for children with severe obesity, with corresponding adjustments, are presented to illustrate implications for researchers and clinicians. Furthermore, R-BMI is presented as a method attempting to address chart challenges related to the extreme BMI. The result is reference curves which share desirable features with established references, while avoiding undesirable curve behavior.

Conclusions: Growth charts present challenges for children living with severe obesity, leading to varying approaches and implications of international references. The proposed R-BMI offers monitoring of children with severe obesity that can be used from birth to adulthood. It relates to adult BMI cut-offs and allows for a terminology, and it has a layout with the potential of highlighting changes which may otherwise go unnoticed.

Place, publisher, year, edition, pages
Sage Publications, 2025
Keywords
adolescents, body mass index, children, growth reference, severe obesity
National Category
Pediatrics
Identifiers
urn:nbn:se:uu:diva-577163 (URN)10.1089/chi.2024.0423 (DOI)001516977600001 ()40569712 (PubMedID)2-s2.0-105009380039 (Scopus ID)
Funder
Swedish Foundation for Strategic Research, CMP22-0014EU, Horizon 2020
Available from: 2026-01-21 Created: 2026-01-21 Last updated: 2026-03-24Bibliographically approved
Tersander, B., Olsson, R., Aydin, B. K., Stenlid, R., Ciba, I. & Manell, H. (2025). Obesity-related subclinical hypothyroidism in childhood: Elevated triglycerides but not basal metabolic rate. Pediatric Research, 98(1), 182-187
Open this publication in new window or tab >>Obesity-related subclinical hypothyroidism in childhood: Elevated triglycerides but not basal metabolic rate
Show others...
2025 (English)In: Pediatric Research, ISSN 0031-3998, E-ISSN 1530-0447, Vol. 98, no 1, p. 182-187Article in journal (Refereed) Published
Abstract [en]

Background

Studies on the associations between obesity-related subclinical hypothyroidism with basal metabolic rate and risk factors of cardiovascular disease in children and adolescents are scarce.

Methods

Retrospective cohort study of children with obesity (n = 294) from the Uppsala Longitudinal Study of Childhood Obesity cohort. Differences in basal metabolic rate quantified by indirect calorimetry, and the cardiovascular risk factors; body mass index, blood lipids, fasting and 2 h oral glucose tolerance test glucose, glycated haemoglobin and insulin resistance, between subjects with and without subclinical hypothyroidism were investigated. The associations of baseline thyroid stimulating hormone (TSH) and ΔTSH with change in cardiovascular risk factors over time were assessed.

Results

Subjects with subclinical hypothyroidism had elevated triacylglycerides but no alterations in basal metabolic rate or other measured cardiovascular risk factors. ΔTSH was positively associated with Δtriacylglycerides, Δtotal-cholesterol and ΔLDL-cholesterol, independently of age, sex, Δbody mass index and ΔT4. In the subclinical hypothyroidism group, 92% of individuals normalised their TSH 0.9–2.9 years later.

Conclusions

Children with obesity and subclinical hypothyroidism did not have an altered basal metabolic rate but elevated triacylglycerides. During the follow-up period, TSH changed in parallel with several blood lipids. Elevated TSH often normalised without pharmaceutical intervention within 3 years.

Place, publisher, year, edition, pages
Springer Nature, 2025
National Category
Endocrinology and Diabetes
Identifiers
urn:nbn:se:uu:diva-574029 (URN)10.1038/s41390-024-03691-6 (DOI)001351972300002 ()39501062 (PubMedID)
Available from: 2026-01-07 Created: 2026-01-07 Last updated: 2026-01-07Bibliographically approved
Aydin, B. K. & Winters, S. J. (2025). Sex Hormone-Binding Globulin and Metabolic Syndrome in Children and Adolescents: A Focus on Puberty. Metabolites, 15(8), Article ID 494.
Open this publication in new window or tab >>Sex Hormone-Binding Globulin and Metabolic Syndrome in Children and Adolescents: A Focus on Puberty
2025 (English)In: Metabolites, E-ISSN 2218-1989, Vol. 15, no 8, article id 494Article, review/survey (Refereed) Published
Abstract [en]

Metabolic syndrome (MetS) is a cluster of conditions, including obesity, insulin resistance (IR), dyslipidemia, and hypertension, that increase the risk of cardiovascular disease (CVD) and type 2 diabetes mellitus (T2DM). While studied often in adults, the increasing prevalence of MetS in children and adolescents underscores the need for its early detection and intervention. Among various biomarkers, sex hormone-binding globulin (SHBG) has gained substantial attention due to its associations with metabolic health and disease. This review provides a comprehensive overview of SHBG and its association with MetS, with a focus on the pediatric and adolescent population. The interplay between SHBG, puberty, and metabolic risk factors is explored, including racial and ethnic variations. SHBG plays a crucial role in transporting sex hormones and regulating their bioavailability and has been found to correlate inversely with obesity and IR, two key components of MetS. Puberty represents a critical period during which hormonal changes and metabolic shifts may further influence SHBG levels and metabolic health. Understanding SHBG's role in early metabolic risk detection could provide novel insights into the prevention and management of MetS.

Place, publisher, year, edition, pages
MDPI, 2025
Keywords
cardiovascular risk, insulin resistance, metabolic syndrome, obesity, pediatric health, puberty, sex hormone-binding globulin, type 2 diabetes
National Category
Endocrinology and Diabetes Cardiology and Cardiovascular Disease
Identifiers
urn:nbn:se:uu:diva-566726 (URN)10.3390/metabo15080494 (DOI)001557983800001 ()40863113 (PubMedID)2-s2.0-105014277591 (Scopus ID)
Available from: 2025-09-08 Created: 2025-09-08 Last updated: 2025-09-08Bibliographically approved
Stenlid, R., Cerenius, S. Y., Wen, Q., Aydin, B. K., Manell, H., Chowdhury, A. I., . . . Bergsten, P. (2023). Adolescents with obesity treated with exenatide maintain endogenous GLP-1, reduce DPP-4, and improve glycemic control. Frontiers in Endocrinology, 14, Article ID 1293093.
Open this publication in new window or tab >>Adolescents with obesity treated with exenatide maintain endogenous GLP-1, reduce DPP-4, and improve glycemic control
Show others...
2023 (English)In: Frontiers in Endocrinology, E-ISSN 1664-2392, Vol. 14, article id 1293093Article in journal (Refereed) Published
Abstract [en]

Background: GLP-1 receptor agonists (GLP-1RA) are increasingly used to treat adolescent obesity. However, the effect on endogenous GLP-1 secretory patterns following treatment in adolescents is unknown. The GLP-1RA exenatide was shown to significantly lower BMI and 2-hour glucose in adolescents with obesity, in the placebo-controlled, randomized controlled trial Combat-JUDO. The aim of this study was to evaluate effects of weekly injections of 2 mg exenatide extended release on secretory patterns of endogenous hormones during OGTT.

Subjects and Measurements: This study was a pre-planned sub-study of the Combat-JUDO trial, set at the Pediatric clinic at Uppsala University Hospital, Sweden and Paracelsus Medical University, Austria. 44 adolescents with obesity were included and randomized 1:1 to treatment:placebo. 19 patients in the treatment group and 18 in the placebo group completed the trial. Before and after treatment, GLP-1, glucose, insulin, glucagon and glicentin levels were measured during OGTT; DPP-4 and proinsulin were measured at fasting. A per-protocol approach was used in the analyses.

Results: Exenatide treatment did not affect GLP-1 levels during OGTT. Treatment significantly lowered DPP-4, proinsulin and the proinsulin-to-insulin ratio at fasting, increased glicentin levels but did not affect insulin, C-peptide or glucagon levels during OGTT.

Conclusion: Weekly s.c. injections with 2 mg of exenatide maintains endogenous total GLP-1 levels and lowers circulating DPP-4 levels. This adds an argument in favor of using exenatide in the treatment of pediatric obesity.

Place, publisher, year, edition, pages
Frontiers Media S.A., 2023
Keywords
obesity, GLP-1, GLP-1 receptor analog, exenatide, pediatrics, glycemic control, GLP-1 receptor agonist, treatment
National Category
Endocrinology and Diabetes Pediatrics
Identifiers
urn:nbn:se:uu:diva-517480 (URN)10.3389/fendo.2023.1293093 (DOI)001101907300001 ()38027106 (PubMedID)
Funder
Swedish Research Council, 2016-01040AstraZenecaEU, FP7, Seventh Framework Programme, 279153DiabetesfondenGillbergska stiftelsen
Available from: 2023-12-11 Created: 2023-12-11 Last updated: 2025-03-27Bibliographically approved
Wen, Q., Stenlid, R., Chowdhury, A. I., Ciba, I., Aydin, B. K., Cerenius, S. Y., . . . Bergsten, P. (2023). Metformin Can Attenuate Beta-Cell Hypersecretion-Implications for Treatment of Children with Obesity. Metabolites, 13(8), Article ID 917.
Open this publication in new window or tab >>Metformin Can Attenuate Beta-Cell Hypersecretion-Implications for Treatment of Children with Obesity
Show others...
2023 (English)In: Metabolites, E-ISSN 2218-1989, Vol. 13, no 8, article id 917Article in journal (Refereed) Published
Abstract [en]

In children with obesity, insulin hypersecretion is proposed to precede insulin resistance. We investigated if metformin could be used to attenuate insulin secretion from palmitate-treated isolated islets and its implication for children with obesity. Human islets were exposed to palmitate for 0.5 or 1 day, when metformin was introduced. After culture, glucose-stimulated insulin secretion (GSIS) was measured. Children with obesity, who had received metformin for over six months (n = 21, age 13.9 +/- 1.8), were retrospectively evaluated. Children were classified as either "reducing" or "increasing" based on the difference between AUC(0-120) of insulin during OGTT before and after metformin treatment. In human islets, GSIS increased after culture in palmitate for up to 1 day but declined with continued palmitate exposure. Whereas adding metformin after 1 day of palmitate exposure increased GSIS, adding metformin after 0.5 days reduced GSIS. In children with "reducing" insulin AUC(0-120) (n = 9), 2 h glucose and triglycerides decreased after metformin treatment, which was not observed in patients with "increasing" insulin AUC(0-120) (n = 12). In isolated islets, metformin attenuated insulin hypersecretion if introduced when islet secretory capacity was maintained. In children with obesity, improved glycemic and lipid levels were accompanied by reduced insulin levels during OGTT after metformin treatment.

Place, publisher, year, edition, pages
MDPI, 2023
Keywords
childhood obesity, hyperinsulinemia, free fatty acids, metformin, human islets, glucose-stimulated insulin secretion, OGTT
National Category
Endocrinology and Diabetes
Identifiers
urn:nbn:se:uu:diva-512839 (URN)10.3390/metabo13080917 (DOI)001056719500001 ()37623862 (PubMedID)
Available from: 2023-10-03 Created: 2023-10-03 Last updated: 2024-09-04Bibliographically approved
Wen, Q., Chowdhury, A. I., Aydin, B., Shekha, M., Stenlid, R., Forslund, A. & Bergsten, P. (2023). Metformin restores prohormone processing enzymes and normalizes aberrations in secretion of proinsulin and insulin in palmitate‐exposed human islets. Diabetes, obesity and metabolism, 25(12), 3757-3765
Open this publication in new window or tab >>Metformin restores prohormone processing enzymes and normalizes aberrations in secretion of proinsulin and insulin in palmitate‐exposed human islets
Show others...
2023 (English)In: Diabetes, obesity and metabolism, ISSN 1462-8902, E-ISSN 1463-1326, Vol. 25, no 12, p. 3757-3765Article in journal (Refereed) Published
Abstract [en]

Aim: To elucidate how proinsulin synthesis and insulin was affected by metformin under conditions of nutrient overstimulation.

Materials and methods: Isolated human pancreatic islets from seven donors were cultured at 5.5 mmol/L glucose and 0.5 mmol/L palmitate for 12, 24 or 72 h. Metformin (25 μmol/L) was introduced after initial 12 h with palmitate. Proinsulin and insulin were measured. Expression of prohormone convertase 1/3 (PC1/3) and carboxypeptidase E (CPE), was determined by western blot. Adolescents with obesity, treated with metformin and with normal glucose tolerance (n = 5), prediabetes (n = 14), or type 2 diabetes (T2DM; n = 7) were included. Fasting proinsulin, insulin, glucose, 2-h glucose and glycated haemoglobin were measured. Proinsulin/insulin ratio (PI/I) was calculated.

Results: In human islets, palmitate treatment for 12 and 24 h increased proinsulin and insulin proportionally. After 72 h, proinsulin but not insulin continued to increase which was coupled with reduced expression of PC1/3 and CPE. Metformin normalized expression of PC1/3 and CPE, and proinsulin and insulin secretion. In adolescents with obesity, before treatment, fasting proinsulin and insulin concentrations were higher in subjects with T2DM than with normal glucose tolerance. PI/I was reduced after metformin treatment in subjects with T2DM as well as in subjects with prediabetes, coupled with reduced 2-h glucose and glycated haemoglobin.

Conclusions: Metformin normalized proinsulin and insulin secretion after prolonged nutrient-overstimulation, coupled with normalization of the converting enzymes, in isolated islets. In adolescents with obesity, metformin treatment was associated with improved PI/I, which was coupled with improved glycaemic control.

Place, publisher, year, edition, pages
John Wiley & Sons, 2023
Keywords
carboxypeptidase E, free fatty acids, human islets, insulin, metformin, prohormone convertase 1/3, proinsulin, proinsulin to insulin ratio (PI/I)
National Category
Endocrinology and Diabetes
Identifiers
urn:nbn:se:uu:diva-513646 (URN)10.1111/dom.15270 (DOI)001065340100001 ()37694762 (PubMedID)
Funder
EU, FP7, Seventh Framework Programme, 279153Vinnova, 2020-02417
Available from: 2023-10-09 Created: 2023-10-09 Last updated: 2024-07-05Bibliographically approved
Stenlid, R., Cerenius, S. Y., Manell, H., Aydin, B. K., Mörwald, K., Gomahr, J., . . . Forslund, A. (2023). Screening for inflammatory markers identifies IL18-Rα as a potential link between exenatide and its anti-inflammatory effect: New results from the Combat-JUDO randomized controlled trial. Annals of Nutrition and Metabolism, 79(6), 522-527
Open this publication in new window or tab >>Screening for inflammatory markers identifies IL18-Rα as a potential link between exenatide and its anti-inflammatory effect: New results from the Combat-JUDO randomized controlled trial
Show others...
2023 (English)In: Annals of Nutrition and Metabolism, ISSN 0250-6807, E-ISSN 1421-9697, Vol. 79, no 6, p. 522-527Article in journal (Refereed) Published
Abstract [en]

Introduction: Obesity is associated with chronic inflammation. Chronic inflammation has also been linked to insulin resistance and type 2 diabetes, non-alcoholic fatty liver disease and cardiovascular disease. Glucagon-like peptide-1 (GLP-1) receptor analogs (GLP-1RA) are clinically used to treat obesity, with known anti-inflammatory properties. How the GLP-1RA exenatide effects inflammation in adolescents with obesity is not fully investigated.

Methods: 44 patients were randomized to receive weekly subcutaneous injections with either 2 mg exenatide or placebo for 6 months. Plasma samples were collected at baseline and at the end of the study, and 90 inflammatory proteins were measured.

Results: Following treatment with exenatide, 15 out of the 90 proteins were decreased, and one was increased. However, after adjustment for multiple testing, only IL18-R alpha was significantly lowered following treatment.

Conclusions: Weekly injections with 2 mg of exenatide lowers circulating IL18-R alpha in adolescents with obesity, which may be a potential link between exenatide and its anti-inflammatory effect in vivo. This contributes to exenatide's pharmaceutical potential as a treatment for obesity beyond weight control and glucose tolerance, and should be further studied mechanistically.

Place, publisher, year, edition, pages
S. Karger, 2023
Keywords
Obesity, Inflammation, GLP-1, IL-18, IL-18R alpha
National Category
Endocrinology and Diabetes Gastroenterology and Hepatology Pediatrics
Identifiers
urn:nbn:se:uu:diva-522506 (URN)10.1159/000534725 (DOI)001097738100001 ()37883939 (PubMedID)
Funder
Swedish Research Council, 2016-01040AstraZenecaEU, FP7, Seventh Framework Programme, 279153DiabetesfondenSvensk Förening för DiabetologiGillbergska stiftelsen
Available from: 2024-02-07 Created: 2024-02-07 Last updated: 2025-03-27Bibliographically approved
Aydin, B. K., Stenlid, R., Ciba, I., Cerenius, S. Y., Dahlbom, M., Bergsten, P., . . . Forslund, A. (2022). High levels of FSH before puberty are associated with increased risk of metabolic syndrome during pubertal transition. Pediatric Obesity, 17(8), Article ID e12906.
Open this publication in new window or tab >>High levels of FSH before puberty are associated with increased risk of metabolic syndrome during pubertal transition
Show others...
2022 (English)In: Pediatric Obesity, ISSN 2047-6302, E-ISSN 2047-6310, Vol. 17, no 8, article id e12906Article in journal (Refereed) Published
Abstract [en]

Background During perimenopause, the rise in serum follicle-stimulating hormone (FSH) is associated with increased adiposity, insulin resistance (IR), and metabolic syndrome (MetS). However, data for the pubertal period, which is characterized by increasing FSH levels and changing body composition, are limited. Objectives To investigate the relationships between FSH and anthropometric changes, IR markers, and development of MetS in the peripubertal period. Methods Uppsala Longitudinal Study of Childhood Obesity (ULSCO) is an ongoing study that aims to understand the factors contributing to childhood obesity and the development of obesity-related diseases. We analysed the subset of participants who were prepubertal at the first visit (n = 95, 77 with obesity). Mean follow-up time was 3.0 +/- 1.4 years. Results Higher serum FSH levels at the first visit were associated with an increased likelihood of elevation in body mass index (BMI SDS) (p = 0.025, OR = 16.10) and having MetS (p = 0.044, OR = 4.67) at the follow-up. We observed nonlinear relationships between varying serum FSH levels and markers of adiposity and IR, especially in girls. At the first visit, when girls were prepubertal, FSH was negatively associated with BMI (beta = -0.491, p = 0.005) and positively associated with sex hormone-binding globulin (SHBG) (beta = 0.625, p = 0.002). With the progression of puberty, negative associations between BMI and SHBG disappeared while FSH became positively associated with HOMA-IR (beta = 0.678, p = 0.025) and fasting insulin (beta = 0.668, p = 0.027). Conclusions Higher serum FSH levels in prepubertal children were associated with an increased risk of MetS development during pubertal transition. Along with nonlinear associations between varying serum FSH levels and IR markers, our results might imply a relationship between FSH and IR of puberty.

Place, publisher, year, edition, pages
John Wiley & SonsWiley, 2022
Keywords
follicle-stimulating hormone (FSH), insulin resistance, metabolic syndrome, obesity, sex hormone binding globulin (SHBG)
National Category
Pediatrics Cancer and Oncology
Identifiers
urn:nbn:se:uu:diva-483576 (URN)10.1111/ijpo.12906 (DOI)000761977600001 ()35226970 (PubMedID)
Available from: 2022-08-31 Created: 2022-08-31 Last updated: 2024-01-15Bibliographically approved
Aydin, B. K., Kadioglu, A., Kaya, G. A., Devecioglu, E., Bas, F., Poyrazoglu, S., . . . Darendeliler, F. (2022). Pelvic and breast ultrasound abnormalities and associated metabolic disturbances in girls with premature pubarche due to adrenarche. Clinical Endocrinology, 96(3), 339-345
Open this publication in new window or tab >>Pelvic and breast ultrasound abnormalities and associated metabolic disturbances in girls with premature pubarche due to adrenarche
Show others...
2022 (English)In: Clinical Endocrinology, ISSN 0300-0664, E-ISSN 1365-2265, Vol. 96, no 3, p. 339-345Article in journal (Refereed) Published
Abstract [en]

Objective Premature adrenarche (PA) has been suggested as a risk factor for future health problems, such as metabolic syndrome and early menarche. However, not all girls with PA have these features and it is not certain who will develop them. We propose that these abnormalities might be identified earlier, even before they are visible. Design Case-control study. Setting Tertiary care hospital. Participants Forty-eight girls with premature pubarche due to PA and age (mean age 7.6 +/- 1.0 years), weight, body mass index (BMI), birth weight and gestational age-matched 49 girls with no palpable breast tissue. Measurements Early pubertal pelvic and breast ultrasonographic changes and their associations with obesity and metabolic parameters were evaluated. Blood samples were collected, breast and pelvic ultrasound examinations were performed and bone ages were assessed. Results Girls with PA were taller and their bone ages were higher (p = .049 and p = .005). Fasting blood glucose, insulin, triglycerides, high-density lipoprotein and low-density lipoprotein cholesterol were not different between the groups. Luteinizing hormone (LH), follicle-stimulating hormone (FSH) and estradiol were not different either. Ultrasonography revealed breast gland tissue in 30% of girls with PA and 5% of controls (p = .006). Uterine volume and endometrial thickness were higher in girls with PA (p = .03 and p = .04). Endometrial thickness was positively associated with serum insulin levels in the whole study group and after adjusting for age, diagnosis, BMI, mean ovarian volume and LH, FSH, estradiol levels, this association remained with a borderline p-value (R-2 = 0.486, p = .050). Conclusions We found early changes in uterus and breast glands of girls with PA and endometrial thickness was positively associated with insulin levels.

Place, publisher, year, edition, pages
John Wiley & SonsWiley, 2022
Keywords
breast ultrasonography, metabolic syndrome, obesity, pelvic ultrasonography, premature adrenarche
National Category
Gynaecology, Obstetrics and Reproductive Medicine
Identifiers
urn:nbn:se:uu:diva-477819 (URN)10.1111/cen.14662 (DOI)000734461100001 ()34918373 (PubMedID)
Available from: 2022-06-21 Created: 2022-06-21 Last updated: 2025-02-11Bibliographically approved
Organisations
Identifiers
ORCID iD: ORCID iD iconorcid.org/0000-0003-0859-1565

Search in DiVA

Show all publications